Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The ask is getting hammered, we might close 0009 today $SAFS
If this is what this stock looks like on Monday, brace for a great week ahead.
Almost 1 Bil shares traded with 2 more hours to go.
$SAFS
This company owns patents to safer guns that soon could be the standard for all Police Departments across the US in the light of Floyd and Defund The Police movement to restore order among rioters and unhappy citizens regarding unnecessary Police murders and gun force used in minor offenses.
$SAFS
Transfer Agent Verified today and the Security Details have also been updated today, we're in business. $SAFS
https://www.otcmarkets.com/stock/SAFS/profile
Monster in the making $SAFS
Big slaps coming in, huge bid at 0004 almost 200 Mil. $SAFS
This company claims to buy 20 mil worth of crypto ? They have no money to do so,..but soon they will,..guess how,..DILUTION my friends..that's how, this stock will be in the trips soon.
What's going on with this company ? It seems that the CEO has another company also http://www.savicell.com/management.html
Savicell Diagnostics™ Ltd. is a majority owned subsidiary of Online Disruptive Technology, Inc. (ODT), a Nevada corporation.
Savicell™ has a first-in-class liquid ImmunoBiopsy™ platform designed for the early detection of disease. The platform identifies multiple diseases and may be used to track treatment effectiveness, including immunotherapy. The Company’s initial focus is on the multi-billion dollar, underserved cancer liquid biopsy market.
Metabolic changes in the immune system modulate cell fate and function, influencing immune response outcomes. These energy changes give the immune system the ability (effector function) to attack disease, including cancer. Diseases produce unique signatures in immune metabolic profiles that ImmunoBiopsy™ uses to distinguish between and within various ailments, such as cancers, autoimmune diseases, and infectious diseases. Savicell’s Liquid ImmunoBiopsy measures the energy changes of the immune system, which are disease-specific, and identifies the ailment.
?
Other liquid biopsy technologies in development evaluate secretions of cancer cells (looking for the criminal) and are more likely to detect late stage cancers. They have technical challenges for early-stage cancers and early cancer screening. In contrast, Liquid ImmunoBiopsy receives data directly from the immune system (interrogating the police). As an immune system test, it is inherently suited for early detection.
Moreover, traditional methods depend on either imaging technology which exposes patients to risks from radiation or costly invasive procedures which are less palatable to patients. In contrast, the Savicell technology, which promises higher throughput blood testing, should place less burden on both patients and the healthcare system.
http://www.savicell.com/latest-news.html
This company is selling itself into a takeover one share at a time, morons.
Switch to E*TRADE or TDAmeritrade, RB and IB are limited in MM's and do not have access to many stocks, small time players. $RGBP
You're way off.
$RGBP made a smart move to get back about $6,000,000 worth of shares, that means the stock will go much higher, they are rectifying past mistakes little by little.
They will not allow this stock to be diluted any further.
That was Zander... lol.
From my experience, when a stock looks beat, is when the stock breaks through,...well $RGBP is at that boiling point.
MULTICORP INTERNATIONAL, INC RETAINS NEW LAW FIRM
Lawyer/Legal Counsel Change Announcement | 04/13/2021
April 13, 2021 11:00 AM PT
https://www.otcmarkets.com/stock/MCIC/news/MULTICORP-INTERNATIONAL-INC-RETAINS-NEW-LAW-FIRM?id=297983
AGOURA HILLS, CA- MultiCorp International, Inc, (OTC Pink: MCIC - News) announced today the company has retained the services of SEC Law Finn.
The company released the following statement. "MultiCorp is extremely excited to announce that they have retained SEC Law Finn and specifically Lance Jon Kimmel Esq. to oversee the company's legal work the company will need in order to become in full compliance with the reporting requirements of OTC Markets. as well as other transactional work. Mr. Kimmel is a very well respected and renowned securities attorney, and we know he will play an integral part of our company's growth moving forward."
Mr. Ben Friedman, President and acting CEO stated, "By engaging Mr. Kimmel and SEC Law Firm, we feel confident that our progress moving forward will be handled properly, both legally and ethically, so the company can ensure the potential move to become fully reporting is completed in the proper manner. positioning us for further opportunities."
About MultiCorp International, Inc.
MultiCorp International, Inc is committed to identifying and acquiring companies that are focused on growth in a variety of medical sectors. We have positioned ourselves to work with global supply chains for the much-needed PPE, medicines, vaccines, and pharmacological products that can help patients stay safe and live healthier lives. The key strategy is to keep the costs of our products down with our existing supply chains and to increase sales contracts by identifying new networks of customers.
CONTACT
MultiCorp International, Inc.
www.multicorpinternational.com
Contact Info
info@multicorpinternational.com
Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines
04/14/2021
CHINA INFRASTRUCTURE CONSTRUCTION CORP.
https://www.otcmarkets.com/stock/CHNC/disclosure
https://backend.otcmarkets.com/otcapi/company/financial-report/278560/content
(a Colorado corporation)
6201 Bonhomme Road, Suite 466S
Houston, TX 77036
Telephone: (832) 606-7500
Fax: (281) 547-7378
Website(s): www.chnc-hdh.com
Email: elizhdh@gmail.com
SIC Code: 8999, 8099
Quarterly Report for the Period Ending February 28, 2021
(the “Reporting Period”)
As of the date hereof, the number of shares of Common Stock outstanding is 7,513,795,009.
As of February 28, 2021 (the Reporting Period end date), the number of shares of Common Stock outstanding was
7,456,295,009.
As of November 30, 2020 (the prior Reporting Period end date), the number of shares of Common Stock outstanding was
7,456,295,009.
As of May 31, 2020 (the most recent fiscal year end date), the number of shares of Common Stock outstanding was
8,732,256,416.
Indicate by check mark whether the Issuer is a shell company (as defined in Rule 405 of the Securities Act of 1933 and
Rule 12b-2 under the Securities Exchange Act of 1934):
Yes: No:
Indicate by check mark whether the company’s shell status has changed since the previous reporting period:
Yes: No:
Indicate by check mark whether a Change in Control of the company has occurred over this reporting period:
Yes: No:
1) Name of the Issuer and its predecessors (if any):
CHINA INFRASTRUCTURE CONSTRUCTION CORP.
The Issuer was formed on February 28, 2003, as a limited liability company under the name Fidelity Aircraft Partners
LLC. On December 16, 2009, it converted to a corporation under the name Fidelity Aviation Corporation, and on August
24, 2009, changed its name to China Infrastructure Construction Corp. On February 28, 2018, it changed its name to
Hippocrates Direct Healthcare, Inc. On July 4, 2018, it resumed its present name. It is active and in good standing in
the state of its incorporation. Management knows of no trading suspension orders issued by the SEC since inception.
The address of the Issuer’s principal executive office appears above.
The address of the Issuer’s principal place of business appears above.
Check box if principal executive office and principal place of business are the same address:
List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: None.
Has the Issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past
five years?
Yes: No:
2
2) Security Information
Trading Symbol: CHNC
Exact title and class of securities outstanding: Common Stock
CUSIP: 16948K106
Par or stated value: Without par value
Total shares authorized: 20,000,000,000 as of date the end of the Reporting Period and as of the
date hereof.
Total shares outstanding: 7,456,295,049 as of the end of the Reporting Period and 7,513,795,009
as of the date hereof.
Number of shares in the Public Float: 1,708,562,904 as of the end of the Reporting Period and as of the date
hereof.
Total number of shareholders of record: 375 and 377 as of the end of the Reporting Period and as of the date
hereof, respectively
Additional class of securities:
Trading Symbol: N/A
Exact title and class of securities outstanding: Series A Convertible Preferred Stock
CUSIP: N/A
Par or stated value: $0.001 per share
Total shares designated: 10,000,000 as Series A Convertible Preferred Stock as of the end of the Reporting Period and
as of the date hereof (of 10,000,000 authorized preferred shares)
Total shares outstanding: 2,500,000 as of the end of the Reporting Period and as of the date hereof.
The holders of the outstanding Series A Convertible Preferred Stock have voting control of the Issuer.
The series is not publicly traded.
Transfer Agent
Pacific Stock Transfer Company
6725 Via Austi Parkway, Suite 300
Las Vegas, NV 89119
Phone: (800) 785-7782
info@pacificstocktransfer.com
Is the Transfer Agent registered under the Exchange Act? Yes: No:
3) Issuance History
A. Changes to the Number of Outstanding Shares
See Exhibit A.
B. Debt Securities, Including Promissory and Convertible Notes
Check this box if there are no outstanding promissory, convertible notes or debt arrangements:
3
Date of
Note Issuance
Outstanding
Balance
($)
Principal
Amount
at Issuance ($)
Interest
Accrued
($)
Maturity
Date
Conversion
Terms (e.g.
pricing mechanism for determining conversion of instrument to shares)
Name of Noteholder
(entities must have
individual with voting / investment
control disclosed).
Reason
for Issuance (e.g.
Loan, Services, etc.)
12/10/20 41,933 45,000 9,148 N/A Not convertible LG Funding, LLC
(Matthew Birnholtz)
Cash
01/14/20 26,690 22,500 2,635 N/A Not convertible Forward Financing,
LLC (Justin Bakes)
Cash
05/22/20 143,200 143,200 4,025 5/22/50 Not convertible Small Business Administration
Cash
06/10/20 106,300 106,300 2,658 6/10/50 Not convertible Small Business Administration
Cash
4) Financial Statements
A. The following financial statements were prepared in accordance with:
U.S. GAAP
IFRS
B. The financial statements for this reporting period were prepared by:
Jorge Verar, CPA
825 Town and Country Blvd., Suite 1200
Houston, TX, 77024
Phone: (713) 931-3080
Email: jverar@cpa.com
Relationship to Issuer: Independent Contractor
The following unaudited consolidated financial statements are provided for the most recent fiscal year:
a. Consolidated Balance Sheets;
b. Consolidated Statements of Operations;
c. Consolidated Statements of Cash Flows;
d. Consolidated Statements of Stockholders’ Deficit; and
e. Notes to Consolidated Financial Statements
The above financial statements are attached as Exhibit B.
5) Issuer’s Business, Products and Services
The Issuer’s business, is (i) educational systems focused on medicinal cannabis, in cities throught the United States of
America and six countries in Latin America and (ii) providing services in therapeutic areas of clinical trials in the United
States. The Issuer was formerly in the business of providing concierge medicine at an affordable price through its
membership-based model in the Houston, Texas, area through its wholly owned subsidiary, Hippocrates Direct
Healthcare, LLC, a Texas limited liability company (“HDH”), the address of which is that of the Issuer, whose contact
information appears above; during the quarter ended August 31, 2020, the Issuer terminated this business.
The president of the Issuer is Dante Picazo, whose contact information is that of the Issuer.
Dealing with difficulties that arose from the exchange in 2018 of $1,844,500 of the Issuer’s obligations for shares of its
common stock (see Note 7 of the Notes to Financial Statements) – among them the difficulty of raising capital in the
face of increasing and unknowable dilution in the value of its shares – diverted management’s attention from normal
business activities. With the elimination of these obligations and the termination of the agreement under which the
4
Issuer was required to issue shares, management intends to devote its full attention to the development of its businesses
and increasing shareholder value.
The COVID-19 pandemic has had a material adverse effect on the Issuer’s educational business because governmental
measures taken to control it resulted in the closing of classrooms and other educational venues, and also hindered the
Issuer’s franchising and consulting activities; however, over the nine-month period ending February 28, 2021, the Issuer’s clinical trials business improved. As the pandemic abates, the Issuer expects that some of these restrictions will
be temporarily or permanently removed. However, it is not yet clear when the Issuer and its customers will be able to
resume normal operations. Assuming that government vaccination programs are successful, this may occur in the near
future. However, if they are not successful, or if they cannot contain infections due to emerging virus variants, these
restrictions could continue indefinitely. The ultimate extent of the impact of the pandemic will depend on future developments, which are highly uncertain and cannot be predicted.
6) Issuer’s Facilities
The Issuer leases premises approximately 4,500 square feet located at 6201 Bonhomme Road, Suites 460S and 466S,
Houston, Texas. The lease currently provides for base rent of $3,382 per month, increasing to (i) $3,529 per month on
July 1, 2020, (ii) $3,676 per month on July 1, 2021, and (iii) $3,823 per month on July 1, 2022, subject to CPI increase.
The lease expires on June 30, 2023. The leased space is shared with the Issuer’s subsidiaries.
In addition, two of the Company’s officers lease 1,400 square feet in Houston, Texas, under a lease the term of which
commenced on February 29, 2020, and will expire on March 14, 2022, at a rent of $3,449 per month; these officers
have made a portion of these premises available to the Company for use as officer space, for which the Company pays
them $2,817 per month.
7) Officers, Directors, and Control Persons
The following information is provided regarding any person or entity owning 5% of more of the Issuer, as well as any
officer and director of the Issuer, regardless of the number of shares that they own, as of the date hereof.
Name of Officer/Director and
Control Person
Affiliation with Company (e.g., Officer/Director/Owner of more
than 5%)
Residential Address
(City/State Only)
Number of
shares owned
Share
type/class
Ownership
Percentage
of Class
Outstanding
Dante Picazo Officer, Director, Owner
of more than 5%
Houston, TX 4,595,467,205 Common
Stock
61.2
Elizabeth Hernandez
Officer, Director, Owner
of more than 5%
Houston, TX 500,000,000 Common
Stock
6.7
Dante Picazo Officer, Director, Owner
of more than 5%
Houston, TX 2,000,000 Series A
Convertible
Preferred
Stock
80.0
Elizabeth Hernandez
Officer, Director, Owner
of more than 5%
Houston, TX 500,000 Series A
Convertible
Preferred
Stock
20.0
Henry Levinski Officer, Director Euless, TX 50,000,000 Common
Stock
0.67
Jose Torres Officer San Juan, PR 40,000,000 Common
Stock
0.53
5
8) Legal/Disciplinary History
A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:
1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding
traffic violations and other minor offenses);
No.
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of
competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such
person’s involvement in any type of business, securities, commodities, or banking activities;
No.
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or
state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated;
or
No.
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or
otherwise limited such person’s involvement in any type of business or securities activities.
No.
B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the Issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include
the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties
thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar
information as to any such proceedings known to be contemplated by governmental authorities.
None.
9) Third Party Providers
The names, addresses, telephone numbers and email addresses of each of the following outside providers are:
Securities Counsel
Barry J. Miller
Barry J. Miller PLLC
547 Merritt Lane
Birmingham, MI 48009
Phone: (248) 232-8039
Email: bjmiller@bjmpllc.com
Accountant or Auditor:
Jorge Verar, CPA
825 Town and Country Blvd., Suite 1200
Houston, TX, 77024
Phone: (713) 931-3080
Email: jverar@cpa.com
Investor Relations Consultant
None
Other Service Providers: Any other service provider(s), including, counsel, advisor(s) or consultant(s) that assisted,
advised, prepared or provided information with respect to this disclosure statement, or provided assistance or services
to the Issuer during the reporting period.
The Issuer’s transfer agent provided reports as to issuances and transfers of the Issuer’s capital stock and the names
of the holders of capital stock and the number of shares respectively held by them.
6
10) Issuer Certification
I, Dante Picazo, Principal Executive Officer and Principal Financial Officer of China Infrastructure Construction Corp., certify
that:
1. I have reviewed this quarterly disclosure statement of China Infrastructure Construction Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, resu
<<<UPDATE !!!>>>
It seems that Valentine Beauty Inc is being reinstated.
In order to find out click on SilerFlume site and search the
https://esos.nv.gov/EntitySearch/OnlineBusinessAndMarkSearchResult
Entity # E0595072008-7 or the
Entity name Valentine Beauty Inc.
once there click the tab "Manage this business"
In order to see changes you have to log in (create an account)
...not long ago, once you click the "Manage this business" tab it would show how much the fees are owed to reinstate the business and get it current....well today I checked again since the volume trading ahs been very unusual lately
and to my surprise it seems that the fees have been paid for and it's pending reinstatement to become ACTIVE once again...and this is the Snapshot to prove it.
The transaction has been COMPLETED (green check) and PENDING.
https://www.nvsilverflume.gov/dashboard/business/1855893
Hold on to your shares, $VLBI has one of the smallest float in the OTC
Nice action here today $HENC
Intensity, Determination and a Magical Unwavering Direction Transports CHNC to Become the Macondo of Medical Cannabis Research
Press Release | 03/17/2021
https://www.otcmarkets.com/stock/CHNC/news/CHNC-Intensity-Determination-and-a-Magical-Unwavering-Direction-Transports-CHNC-to-Become-the-Macondo-of-Medical-Cannabi?id=294088
HOUSTON, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- China Infrastructure Construction Corp. (OTC: CHNC) https://www.chnc-hdh.com/: With all hands on deck, and an axiomatically relentless effort to endure and continue to withstand the test of time, CHNC intends to continue to improve its overall performance. And, in addition to its short and long-term promising projects, as well as the need and desire to provide our shareholders and partners a great return on their investment; suitably, the board of directors at CHNC by virtue of a cash transaction sealed a buyback of 4 billion shares, with no dilution effect to shareholders. All the same, shareholders can rest assured with shrewd knowledge that the ownership of the company that each one has in their possession has not been reduced or diluted. The four billion shares acquired have now become part of the treasury of the company, says Elizabeth Hernandez, COO of CHNC. This move resembles the re-acquisition by a company of its own shares known as a “Buyback”. Some of you may remember that such transactions used to be deemed as market manipulation, and that’s why it was illegal until 1982. After that, buybacks became a frequent practice, and are better used because of different reasons such as ownership consolidation, undervaluation, financial statements, even for compensation purposes (for instance an Employee Stock Option Plan). Among the companies that have performed a buyback we find Apple, Microsoft, Oracle, Berkshire Hathaway, and others. Without a doubt, buybacks have slowly overtaken dividends as a preferred way to increase shareholder value.
On a different note, we continue to nurture and water the collegiate development of our educational training programs aimed at a different public than just consumers/experts of cannabis, whereby, we are now educating doctors, businessmen, legislators, and politicians. Before the present, medical cannabis as a stable business was just a multicolor hallucination, or a political suicide for public office legislators, but with patience and education, cannabis as medication has slowly gained weight and relevance. As an example with accredited educational standards, Colombia, a country with a well-known bloodstained historical war on drugs, swiftly took a great step of legalizing cannabis for medical purposes in 2017, gradually changing to be one of the most profitable educational destinations of our franchises and academic venues. Therefore, we are pleased to inform of the novel and renewed alliances made with educational entities such as UTADEO (Universidad Jorge Tadeo Lozano) located in Bógota-Colombia, which for 3 years has collaborated with our firm and featured our educational 12 and 14 weeks Diplomado Curricula, making us pioneers of our Accredited University Diploma Courses, to certified cannabis pedagogical programs in Latin America. It should be noted that these curriculums have had an international reach, with students, health professionals, agronomists, chemists, and patients from countries such as Brazil, Spain, France, Uruguay, Mexico, Peru, USA, and Chile traveling from around the world to Colombia to attend our Diplomados.
Close to the wind, once more we proudly announce our freshest and right out of the oven alliance with the UTB (Universidad Tecnológica de Bolívar), located in Cartagena Colombia, where we will continue to bet and plant seeds for awareness of cannabis as medicine, research and education. What’s more, we intend to expand our participation to include international exchange programs, as well as one week summer symposiums with Cannabis leaders-executives from around the world.
If one has ever read “One Hundred Years of Solitude”, you will remember that the magical realism of this book, awarded with a Nobel Literature Prize, was inspired by the history of the Caribbean. Hence, given the circumstances, CHNC intends to write a second live oracle edition of the celebrated manuscript, by helping “write a page in the history of cannabis in Colombia that will not be tainted or stained with blood,” says Anne Graham, In-house Legal Counsel for CHNC. Instead, a scientific story that describes the palliative effects of the flower as medication for the medicinal use of those that have been left behind by traditional medication, in other words “out with the opioids in with the cannabinoids,” says Dr. Julian Gonzalez, Advisory Board Member of CHNC. Whereby, we can create a new paradigm shift and an introduction to medical therapies, employment and financial opportunities to the magical land of “Macondo”. And so, our new academic alliance will commence its history in the cities that inspired the magical story; as well Students from all over the world who participate in our diplomas will have the opportunity to visit Cannabis cultivation facilities in Santa Marta, Colombia, (where some of the most recognized cannabis strains in the world originated, Colombian Gold), they will also be able to participate in exchanges with already operating cannabis enterprises within the region.
For sure, a lot of progress has taken place in the Latin land, but cannabis goes beyond borders via its transmutation reconstruction and by slowly liberating itself. Be that as it may, the United States is not staying behind in this process, with a 35% increase over 2019, legal medical and adult-use cannabis proceeds that reached the amount of $12.9 billion, and according to statistical outlooks, the sales will hit $20.4 billion by 2022. What is more, with continued legalization taking place in parts of the USA, Mexico, and other countries; plus, if we consider the unfortunately still illegal marijuana sales during the last years, we apparently are in front of industry revenues in the vastness of $48.5 billion by 2022, with a quantitative outlook with a pledge promise of a boundless place to be, for a research and educational firm.
Therefore, CHNC reiterates its commitment to the medical cannabis industry, to patients affected by a variety of conditions who seek a natural and efficient alternative to healthcare and to professionals who wish to learn or enhance their knowledge; similarly, to those whose interest was awakened and seek answers to their uneducated present condition. Precisely, this is why we are as pleased as a dog with two tails about the fact that our project "Phytotherapy with cannabinoids for the reduction of symptoms of COVID-19" is presently being sent to executives from different corporations and countries. Our firm is finally beginning to have a life of its own! says Henry Levinski, Treasurer of CHNC. The communiqué that is being sent to some of the most recognized companies, people or funds in the world, can be read at this link https://www.chnc-hdh.com/covid-19. Likewise, for all those interested in knowing who we are sending the Phytotherapy presentation to, can see the list at the following link https://www.chnc-hdh.com/covid-19-contact.
More to the point, please know that our digital publications Cannamed and Cannalaw will soon be enjoying a new sister publication that has been baptized by the name Cannatrade, focusing solely on the up-to-the-minute business aspects of the industry. The cannabis trade is constantly changing; we are surrounded by new businesses, legal challenges and ground-breaking discoveries on a daily basis without any precedent. We understand how overwhelming it can be to keep up with a market that is evolving more and more by the minute and is now an international commerce. Therefore, Cannatrade is attentive to the exciting changes that are stirring the industry such as how is the cannabis stock market, what companies are growing and are attractive to invest, what international businesses are being conducted, what are the alliances that have materialized between countries. With Cannatrade we wish to give the user updated financial information, knowledge on what is out there and how they can by education become part of the speed of light global evolution. For a limited time only, if you would like to apply for an early subscription visit the following link https://www.chnc-hdh.com/canna-trade.
With our new magazine we wish to continue to grow as our current digital publications that have presently reached distribution in an astonishing 70 countries (Andorra, Algeria, Arab Emirates, Argentina, Australia, Austria, Bahrain, Bolivia, Bonaire, Brazil, Cabo Verde, Canada, Chile, Colombia, Costa Rica, Curacao, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, France, Germany, Guinea, Equatorial Guinea, Greece, Guatemala, Honduras, Iraq, Ireland, Israel, Italy, Ivory Coast, Jamaica, Jordan, Kuwait, Lesotho, Lebanon, Libya, Mexico, Morocco, Malta, Mauritania, Nicaragua, Norway, New Zealand, Palestinian Territories, Panama, Paraguay, Peru, Portugal, Puerto Rico, Qatar, Saudi Arabia, Spain, Syria, Sudan, Sweden, Switzerland, Tunisia, United Kingdom (UK), United States, Uruguay, Venezuela, Yemen and Zambia)... and what is yet to come.
Conclusively, CHNC would like to thank all of our shareholders for their persistent support, inspiration and constant communication that at times for legal reasons we cannot always respond. But be certain that we are here with every intention to victoriously make it to the fourth quarter. “Equally important, my gratitude to our front-line partners that tirelessly provide us with their indomitable exertion and support so that we can day by day taste the fruits of our healthy disregard for the impossible.” And call to mind that "Every day is an opportunity to innovate and work for global health, from the field of alternative medicine," says Dr. Jose Torres, Director and International Medical Director of CHNC.
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.
For more information contact us at:
info@pharmacologyuniversity.com
817/528-2475 for English
214/733-0868 for Spanish
I see some nice action today $CHNC
I think we've already seen the worse of this stock, I'm confident it will only go up from here $RGBP
That's if people buy it.
I agree, they suck at customer service.
And down we go.
I hope you guys voted to cut that tumor out of this business already, I want some better news, like... we dropped the losing subsidiary, this needs to be above a dollar soon.
This company is good in the Biotech world, but they suck when it comes to business, soon they will lose their voting power to shareholders cause they keep selling their shares, they will work for me soon...I'm buying more...boy am I.
By now is the company diluting, nobody else.
Buyback=Dilution.
What's wrong with this company, I don't hear a peep from them, has anyone tried to make contact ?
Won't break 25 for a long time, too many shares bought in the 0014 range, that's a nice flip at these levels, it needs a few more days to spread the float evenly, those convertible notes destroyed the float from 01 all the way down.
You convinced me to get out, next time...shut it.
I'm out, nice flip, thank you fellas, GLTA
Keep telling people how cheap you bought and see how fast they dump on you.
That's the way it should trade everyday $CBDL
Etrade, if you gotta ask, I assume you have Robinhood, the worst platform ever.
Old news about Regen BioPharma from 2018, but worth reading to understand what this company is about, this company might have the cure for AIDS...let me know what you think about it.
Regen BioPharma, Inc. Reports Success of its NR2F6 Small Molecule Screening Program for Treating Autoimmune Diseases
PR Newswire
SAN DIEGO, August 30, 2018
SAN DIEGO, August 30, 2018 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently identified novel chemical compounds appear to inhibit NR2F6 and show potential for treating autoimmune diseases such as Lupus.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) which may be important in developing therapies for treating autoimmune diseases like Lupus. Therapies that manipulate NR2F6 show potential to act as a cancer stem cell differentiators, potentially transforming cancer stem cells into normal cells.
The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"We have identified a handful of compounds representing three different structural classes that inhibit NR2F6 in our primary screening assay," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "They exhibited a dose-dependent inhibitory effect on NR2F6 without cytotoxicity. Our next steps will focus on determining what effect they have on human immune cells."
David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. added, "This is exciting for Regen to reach this point in its goal for developing therapies that treat autoimmune diseases. These compounds recently identified should provided us the basis to further refine our screening for successful antagonists in the development of immunologically based cancer therapies."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact Information
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
http://www.regenbiopharma.com
Regen BioPharma (RGBP) Stock Move Towards 10 Cents On Huge Volume
April 12, 2021 Anthony Gonzales
https://ownsnap.com/regen-biopharma-rgbp-stock-move-towards-10-cents-on-huge-volume/
As we all know penny stocks make a huge move, earlier this year we have seen a lot of big movers like Humbl Inc (OTC: HMBL), Asia Broadband (OTC: AABB), and many more. Well, this month we have a new name Regen BioPharma Inc (OTC: RGBP). The stock is up for the third consecutive day.
At the time of writing, RGBP stock is up another 165% on massive volume. After today’s gain, the stock has soared 430% in just 2 trading sessions. Moreover, the stock is trading at a 52-week high now, which makes the momentum further stronger. The company’s market capitalization has been soared to $41.70 million from about $8 million last week.
Related: Why Is TPT Global Tech (TPTW) Gaining Momentum This Week?
So what drove the stock so crazy? Well, On Friday, the stock attracted many penny stock lovers after the company disclosed a licensing deal for its pancreatic cancer treatment. So considering the news, the stock’s run-up looks genuine. However, one should not forget, penny stocks are very risky and carry huge risks. So, get ready for more volatility as no one can predict where can the stock go from here on. So, RGBP stock could suit only brave traders.
Related: Is Regen BioPharma (RGBP) the Right Penny Stock To Trade This Week?
https://ownsnap.com/is-regen-biopharma-rgbp-the-right-penny-stock-to-trade-this-week/
See You, hate to be you. On my way to 10 cents, Catch me if you can $RGBP
The stock broke 8 cents yesterday, guess where is going again ?...you guessed it...0.10 cents $RGBP
Thank you for the 0.044's, see you loser, keep selling, I'll buy it $RGBP